Shares of Glaukos retreated after the company forecast disappointing sequential revenue growth for its iDose product in the fourth quarter. The stock declined 12% to $97 in after-hours trading on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback